Phase
Startup
Selcis Biopharma
Selcis BioPharma develops a technology where SCFAs, short chain fatty acids, can be delivered to the colon and potentially prevent or restore gut homeostasis. SCFAs are considered to promote good gastrointestinal health.
Alexandra Ellervik has a M.Sc. in Molecular Biology and was awarded a PhD in neurophysiology in 2004 at Lund University. After two years as a postdoctoral fellow at the University of Zurich in Switzerland, she was employed within the private business as project manager, business developer and marketer and also elected as board member. Dr Ellervik is currently employed as project manager at RhoVac AB and joined Selcis BioPharma 2021.
Excellence in solid material analysis
Amplify the efficacy of pharmaceutical treatments
Simplify medicine information through digital services
A "check-in buddy" for the elderly
Excellence in inhaler performance
Behavioral coaching app
Antibiotic-free treatment for vaginal bacterial infections
Digital tool for meeting an allergy doctor
Cutting-Edge Histological Solutions for Pharma Industry
Digital communication tool for titrating medicine
Mobile systems for movement analysis
Innovative solutions for better health care
GPS tracker system for elderly
Drug delivery platform
Healthtech for children with eating challenges
Digital health management tool
Short chain fatty acids can be delivered to the colon
Therapeutics after stroke
Starch pickering emulsion technology
Measuring thyroid hormone levels
Gene editing analysis solution
Cost-effective & rapid COVID-19 diagnostic test
eHealth clinic for obesity treatment
